通过天眼查大数据分析，北京英诺特生物技术股份有限公司共对外投资了9家企业，参与招投标项目216 次，知识产权方面有商标信息33条，专利信息46条，此外企业还拥有行政许可42个。 本文源自：市场资讯 作者：智投君 资金流方面，英诺特近5日主力资金流入1398.72万元，区间涨幅6.68%；近10日主力资金流入1126.64万 元，区间涨幅2.28%。 天眼查商业履历信息显示，北京英诺特生物技术股份有限公司，成立于2006年，位于北京市，是一家以 从事批发业为主的企业。企业注册资本13645.8196万人民币，实缴资本13606.0816万人民币。公司法定 代表人为张秀杰。 12月22日，沪深两融数据显示，英诺特上周累计获融资净买入额2695.92万元，居两市第196位，上周融 资买入额5240.87万元，偿还额2544.95万元。 英诺特所属概念板块包括：生物制品、北京板块、沪股通、融资融券、痘病毒防治、流感、体外诊断。 ...

因流感进ICU，肺里堵满"痰栓" 引发网友关注 11岁男孩 本文转自【央视网】； "早上开始发烧，晚上肺就白了" 近日，浙江11岁男孩 早上发烧，晚上就"白肺" "一天时间，这个孩子从轻微发烧咳嗽，直接发展到肺堵死、喘不上气，去鬼门关走了一遭！"浙江大学医学院附属儿童医院杨子浩主任医师披露了这个男 孩的遭遇。 2025年12月1日早上，11岁男孩小宇（化名）开始发烧，最高到38.9℃，伴有轻微咳嗽和喘息。家人以为是感冒，给孩子服用头孢、易坦静、柴胡等药， 却没想到病情会在一天内急转直下。 到12月1日晚上，小宇咳嗽加剧，喘得越来越急，还喊胸口疼，没法躺平。 12月2日早上，孩子呼吸急促、嘴唇发紫、精神不振，家人急忙将他送到浙江大学医学院附属儿童医院急诊。这时，距小宇出现发热，刚好差不多一天。 急诊检查结果让医护人员瞬间紧张：验血显示炎症指标大幅上升，胸片发现左侧肺叶几乎不工作了，影像学中变成大片白色，即通常所说的"白肺"，意味 着肺功能严重受损，孩子已经缺氧，随时有窒息危险。 图：影像显示肺白了一半 "这是流感合并细菌感染引起的严重肺炎，同时发生了坏死性喉气管支气管炎，并有严重并发症，若不及时处理，几小时就可 ...

本周流感活动水平出现下降，甲型H3N2为主要毒株 国家卫健委12月19日举行新闻发布会，专家介绍，当前我国呼吸道传染病疫情仍然处于高发季节。从中国疾控中心发布 的监测报告来看，流感病毒是我国急性呼吸道传染病主要流行的病原体，呼吸道合胞病毒、鼻病毒亦存在一定水平的活 动。本周我国流感活动水平出现下降，但是总体仍处于高流行水平。从哨点医院流感病毒检测阳性率情况来看，门急诊 流感样病例和住院的严重呼吸道感染病例当中，流感病毒检测阳性率均居首位。甲型H3N2为主要的流感毒株。从各省 监测情况来看，南方部分省份疫情达峰时间略晚于北方。总体来看，各省份流行强度处于动态变化之中，请大家重视并 做好个人和家人的防护措施。 医保局："医保影像云"四项规范向社会征求意见 据国家医保局网站12月19日消息，为解除群众疾病医疗后顾之忧，更好维护医保参保人权益，国家医保局依托全国医保 信息平台，组织开展医保影像云系列规范研究，制定形成了四项《"医保影像云"基础规范》，公开征求社会意见。本次 规范编制的核心目标是加快推进医保影像云高质量建设，构建影像检查数据全国存储、机构调阅、参保人查阅的数字化 服务平台，支撑全国定点医疗机构间医保支付 ...

Core Viewpoint - The company, Huaren Health, has shown significant stock performance with a 13.11% increase in share price and a trading volume of 1.314 billion yuan, indicating strong market interest and potential growth opportunities [1]. Group 1: Company Overview - Huaren Health is based in Hefei, Anhui Province, and was established on June 29, 2001. It was listed on March 1, 2023, and primarily engages in pharmaceutical agency, retail, and terminal procurement [7]. - The company's main revenue sources are 97.60% from traditional Chinese and Western medicines, with the remaining 2.40% from other supplementary products [7]. - As of September 30, 2023, Huaren Health had 20,100 shareholders, a decrease of 22.86% from the previous period, with an average of 7,422 circulating shares per person, an increase of 29.64% [7]. Group 2: Financial Performance - For the period from January to September 2023, Huaren Health achieved a revenue of 3.892 billion yuan, reflecting a year-on-year growth of 19.06% [7]. - The net profit attributable to the parent company was 157 million yuan, representing a significant year-on-year increase of 45.21% [8]. - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [9]. Group 3: Market Position and Trends - The company has established a presence on major e-commerce platforms in China, including JD.com, Pinduoduo, and Meituan, alongside Alibaba's Tmall and Ele.me, indicating a robust distribution strategy [2]. - Huaren Health's subsidiary, Jiangsu Shenhua Pharmaceutical Co., specializes in the research, manufacturing, and sales of fungal biopharmaceuticals, positioning the company well within the biotechnology and new pharmaceutical sectors [3]. - The company is focused on innovative drugs and high-end generic drug development, with 22 research projects in progress as of June 30, 2023 [2].

来源：新浪证券-红岸工作室 12月10日，ST诺泰涨0.37%，成交额7379.64万元，换手率0.61%，总市值120.16亿元。 异动分析 CRO概念+肝炎概念+减肥药+流感+人民币贬值受益 1、公司的定制类产品业务主要是CDMO业务,CDMO(合同研发与生产组织)更强调生产工艺的研发和技 术创新能力,是高技术壁垒的工艺研发能力与规模生产能力的深度结合。 2、公司旗下产品注射用胸腺法新用于治疗慢性乙型肝炎。 3、2023年6月9日公司互动：公司自主研发的GLP-1受体激动剂抗糖尿病和减肥一类新药SPN0103-009注 射液已取得药物临床试验批准通知书。 资金分析 今日主力净流入238.37万，占比0.03%，行业排名29/159，连续2日被主力资金增仓；所属行业主力净流 入-6.15亿，连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入238.37万907.06万-1698.09万-2918.47万-7786.96万 主力持仓 主力轻度控盘，筹码分布较为分散，主力成交额5150.12万，占总成交额的11.57%。 技术面：筹码平均交易成本为41.23元 该股筹码平均交易成本为41. ...

Core Viewpoint - The current flu season in China is experiencing a significant rise in activity, primarily driven by the H3N2 subtype, which accounts for over 95% of cases, while H1N1 and B-type influenza viruses are also present in smaller numbers [3][4]. Group 1: Flu Virus Dynamics - The main change in this flu season is the dominance of the H3N2 strain, which has replaced H1N1 as the primary circulating virus [4]. - The H3N2 strain has not seen large-scale outbreaks in the past two years, leading to a general lack of immunity in the population, thus increasing the risk of infection [4]. - Even though the H3N2 subtype name remains the same, the virus undergoes minor antigenic changes each season, making it a "familiar new enemy" for the immune system [4]. Group 2: Flu Season Statistics - In the 2025-2026 flu season (as of November 2025), H3N2 is the absolute dominant strain, while H1N1 was the main strain in the previous season, accounting for over 99% [5]. - The current flu activity is rapidly increasing, with many provinces reaching moderate to high levels of circulation, contrasting with the previous season, which was relatively stable with localized outbreaks [5]. - The high-risk population this season includes children aged 5-14, who are showing a significant increase in cases, whereas the previous season had a more evenly distributed age demographic [5]. Group 3: Antiviral Medications - Oseltamivir and baloxavir marboxil should not be used as long-term preventive medications; oseltamivir is effective only during the treatment period, and improper use may increase the risk of resistance [6][8]. - In special cases, such as households with individuals over 65 years old, oseltamivir may be considered for preventive use if someone in the household is infected [8]. - It is crucial to take antiviral medications within 48 hours of symptom onset to shorten the duration of illness and reduce the risk of severe outcomes [8]. Group 4: Vaccination Recommendations - The 2025 flu vaccine covers the H3N2 strain and has an efficacy rate of 60%-80%, significantly reducing the risk of severe illness even if infection occurs [10].

Core Viewpoints - The A-share market saw all three major indices rise on Friday, with the Shanghai Composite Index up by 0.7%, the Shenzhen Component Index up by 1.08%, and the ChiNext Index up by 1.36%. The total trading volume in the Shanghai and Shenzhen markets reached 1,725.659 billion yuan [1][6] - In terms of industry performance, non-bank financials, metals, and machinery equipment led the gains, while banking, public utilities, and transportation sectors lagged behind [1][6] - The Hang Seng Index in Hong Kong rose by 0.58%, and the Hang Seng Technology Index increased by 0.84%. In overseas markets, the three major US indices also saw collective gains, with the Dow Jones up by 0.22%, the S&P 500 up by 0.19%, and the Nasdaq up by 0.31% [1][6] Important News - As of the end of November, China's foreign exchange reserves stood at 33,464 billion USD, an increase of 30 billion USD from the end of October, marking a rise of 0.09%. This figure has remained above 3.3 trillion USD for four consecutive months and is the highest since December 2015. Additionally, the central bank's gold reserves reported at 7,412 million ounces, with an increase of 30,000 ounces month-on-month, marking the 13th consecutive month of gold accumulation since last November [2][7] - A draft of the "Guidelines for Performance Evaluation Management of Fund Management Companies" has been issued, which strengthens performance assessments and links various indicators to profitability. The regulations require that the proportion of investments by executives and fund managers be increased, with at least 30% of their annual performance compensation tied to purchasing their own company's funds. Fund managers' performance compensation will be closely linked to fund performance, with significant reductions in compensation for those whose products underperform benchmarks by over ten percentage points in the past three years [2][7] Industry Insights - In December, TV panel prices are expected to stabilize, with a warming demand anticipated next year. According to data from Lottu Technology, the prices of LCD TV panels from major manufacturers saw an increase in November, with small sizes rising by 0.5-1 USD and medium to large sizes by 2-3 USD. Although the settlement price is expected to decline, the rate of decline is anticipated to narrow [8][9] - The upcoming sports events in 2026, such as the Winter Olympics and the World Cup, are expected to boost demand for panels, leading downstream manufacturers to stock up in advance, which will provide support for LCD TV panel prices. The demand for large-sized displays continues to grow, with a projected 6% year-on-year increase in global display panel area demand in 2026 [9][10] - The operating rates of LCD panel manufacturers remain high, and the depreciation pressure on production lines is expected to ease, improving operational pressures. In October 2025, the global shipment of large-sized LCD TV panels reached 20.6 million units, an 8% year-on-year increase, despite a 4.8% month-on-month decline [10][11]

Core Viewpoint - The flu season in China has intensified, with 17 provinces reporting high levels of flu activity, prompting health authorities to enhance monitoring and response measures [1][3][11] Group 1: Flu Activity and Impact - Currently, 17 provinces in China are experiencing high flu activity, while the remaining provinces are at moderate levels [3] - The positive rate of flu virus detection among patients with flu-like symptoms in outpatient and emergency departments has reached 51%, which is below the highest levels recorded in the past three years [3] - The percentage of flu-like cases reported by sentinel hospitals nationwide is 9.6%, with the top three detected pathogens being influenza virus, rhinovirus, and respiratory syncytial virus [6] Group 2: Public Health Response - The number of flu outbreaks this season is significantly higher than the previous season, particularly in crowded settings such as schools and nursing homes [9] - Health authorities are urging the public to get vaccinated against the flu to prevent infection and reduce the risk of severe illness [9] - The National Health Commission and the CDC have deployed measures to strengthen monitoring and response, ensuring that medical institutions are adequately staffed and equipped to handle the increased demand for services [11]

Core Insights - The flu season this year is notably more severe and earlier than in previous years, with a significant increase in flu-like cases reported [1][3][4]. Group 1: Flu Activity and Statistics - Flu-like cases in outpatient settings have been rising, with an expected peak around mid-December [1]. - In the 48th week of 2025, there were 1,541 reported outbreaks of flu-like cases, a stark increase from just 31 outbreaks in the same week of 2024, representing nearly a 50-fold increase [5]. - The proportion of flu virus detected in respiratory samples has surged to 51.1% in the 48th week of 2025, compared to only 7% in the same week of 2024 [7]. Group 2: Virus Strains and Resistance - The H3N2 strain accounts for over 99% of the flu cases, with reports of drug-resistant strains emerging [5][12]. - There is a notable increase in the sales of antiviral medications, with a reported over 500% increase in purchases of flu antiviral drugs in mid-November [10]. Group 3: Vaccination and Prevention - Vaccination remains an effective method to reduce flu risk, with various flu vaccines being safe and effective [5][16]. - Current seasonal flu vaccines are based on egg-cultured antigens and are categorized into inactivated vaccines and live attenuated vaccines, both of which are deemed safe for different populations [20][22]. - Despite concerns about the effectiveness of vaccines against the K subclade, existing vaccines still provide significant protection against flu-related complications, especially in children [31][32]. Group 4: Public Health Recommendations - Good hygiene practices, such as handwashing and wearing masks, are essential in preventing the spread of the flu [33]. - Individuals are encouraged to seek timely medical attention if flu-like symptoms appear, and to adhere to prescribed antiviral treatments [35][36].

会上，有记者提问，流感超过一周还有传染性吗？它的传染期一般是多久？如何自行判断已没有传 染性，可以自行返岗和返校？ 中国疾病预防控制中心病毒病所研究员王大燕表示，流感患者和隐性感染者是流感的主要传染源， 从潜伏期末到急性期都有传染性，一般来说，排毒时间多为3-7天，儿童、免疫功能损伤以及危重症患 者排毒时间可能超过一周。 人民网北京12月5日电 （记者乔业琼）国家卫生健康委召开新闻发布会，介绍时令节气与健康（大 雪）有关情况，并回答记者提问。 王大燕介绍，流感主要以发热、头痛、肌肉关节酸痛等起病，发热可以达到39℃-40℃，可以有咽 喉痛、干咳、鼻塞、流涕，可以出现畏寒、寒战、乏力、食欲减退等全身症状，部分患者的症状轻微或 者无症状。无并发症者多于发病3-5天后发热逐渐消退，全身症状好转，但是咳嗽、体力恢复往往需要 更长时间。 王大燕提醒，感染流感后，症状较轻的可以居家休息，但如果出现39℃以上的高热、使用退热药物 效果不佳，或者有剧烈咳嗽、呼吸急促、胸闷、憋气等严重症状，或出现剧烈头痛、频繁呕吐、意识模 糊等，需要及时就医。老年人、婴幼儿、慢性病者以及孕妇等人群感染流感后较易发展为重症或者危重 症，应当高度 ...